Olga Selioutski1, Katherine Grzesik2, Olga N Vasilyeva3, Ágúst Hilmarsson4, A James Fessler5, Lynn Liu5, Robert A Gross5. 1. Department of Neurology, Strong Epilepsy Center, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA. Electronic address: olga_selioutski@urmc.rochester.edu. 2. Department of Biostatistics, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA. 3. Department of Pharmacy, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA. 4. Landspitali University Hospital, Slettuvegi, Reykjavik, Iceland. 5. Department of Neurology, Strong Epilepsy Center, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
Abstract
PURPOSE: Due to the complex pharmacokinetic profiles of phenytoin (PHT) and fosphenytoin (FOS), achieving sustained, targeted serum PHT levels in the first day of use is challenging. METHODS: A population based approach was used to analyze total serum PHT (tPHT) level within 2-24h of PHT/FOS loading with or without supplementary maintenance or additional loading doses among PHT-naïve patients in the acute hospital setting. Adequate tPHT serum level was defined as ≥20μg/mL. RESULTS: Among 494 patients with 545 tPHT serum levels obtained in the first 2-24h after the loading dose (LD), tPHT serum levels of either <or≥20μg/mL were observed along wide and overlapping cumulative dose ranges. Among those receiving 15-20mg/kg and 20-55mg/kg weight-based loading dose, 63% and 51% respectively did not attain tPHT serum level of ≥20μg/mL even within the first 6h of treatment. For the 393 available concomitant free and total serum PHT levels, correlation was weak, r=0.36. CONCLUSION: Close laboratory surveillance and PHT/FOS dose adjustments are recommended to ensure adequate and sustained tPHT serum levels early in treatment. Free serum PHT level is the preferred method of drug monitoring.
PURPOSE: Due to the complex pharmacokinetic profiles of phenytoin (PHT) and fosphenytoin (FOS), achieving sustained, targeted serum PHT levels in the first day of use is challenging. METHODS: A population based approach was used to analyze total serum PHT (tPHT) level within 2-24h of PHT/FOS loading with or without supplementary maintenance or additional loading doses among PHT-naïve patients in the acute hospital setting. Adequate tPHT serum level was defined as ≥20μg/mL. RESULTS: Among 494 patients with 545 tPHT serum levels obtained in the first 2-24h after the loading dose (LD), tPHT serum levels of either <or≥20μg/mL were observed along wide and overlapping cumulative dose ranges. Among those receiving 15-20mg/kg and 20-55mg/kg weight-based loading dose, 63% and 51% respectively did not attain tPHT serum level of ≥20μg/mL even within the first 6h of treatment. For the 393 available concomitant free and total serum PHT levels, correlation was weak, r=0.36. CONCLUSION: Close laboratory surveillance and PHT/FOS dose adjustments are recommended to ensure adequate and sustained tPHT serum levels early in treatment. Free serum PHT level is the preferred method of drug monitoring.
Authors: Tracy Glauser; Shlomo Shinnar; David Gloss; Brian Alldredge; Ravindra Arya; Jacquelyn Bainbridge; Mary Bare; Thomas Bleck; W Edwin Dodson; Lisa Garrity; Andy Jagoda; Daniel Lowenstein; John Pellock; James Riviello; Edward Sloan; David M Treiman Journal: Epilepsy Curr Date: 2016 Jan-Feb Impact factor: 7.500
Authors: D M Treiman; P D Meyers; N Y Walton; J F Collins; C Colling; A J Rowan; A Handforth; E Faught; V P Calabrese; B M Uthman; R E Ramsay; M B Mamdani Journal: N Engl J Med Date: 1998-09-17 Impact factor: 91.245
Authors: Robert Silbergleit; Valerie Durkalski; Daniel Lowenstein; Robin Conwit; Arthur Pancioli; Yuko Palesch; William Barsan Journal: N Engl J Med Date: 2012-02-16 Impact factor: 91.245
Authors: Abhishek G Sathe; Usha Mishra; Vijay Ivaturi; Richard C Brundage; James C Cloyd; Jordan J Elm; James M Chamberlain; Robert Silbergleit; Jaideep Kapur; Daniel H Lowenstein; Shlomo Shinnar; Hannah R Cock; Nathan B Fountain; Lynn Babcock; Lisa D Coles Journal: J Clin Pharmacol Date: 2021-01-12 Impact factor: 2.860
Authors: Abhishek G Sathe; Richard C Brundage; Vijay Ivaturi; James C Cloyd; James M Chamberlain; Jordan J Elm; Robert Silbergleit; Jaideep Kapur; Lisa D Coles Journal: Clin Transl Sci Date: 2021-05-01 Impact factor: 4.689